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Abstract: Biomarkers of breast cancer are necessary for prognosis and prediction to chemotherapy. Prognostic biomarkers provide 
information  regarding  outcome  irrespective  of  therapy,  while  predictive  biomarkers  provide  information  regarding  response  to 
therapy. Candidate prognostic biomarkers for breast cancers are growth factor receptors, steroid receptors, Ki-67, cyclins, urokinase 
plasminogen activator, p53, p21, pro- and anti-apoptotic factors, BRCA1 and BRCA2. But currently, the predictive markers are 
Estrogen and Progesterone receptors responding to endocrine therapy, and HER-2 responding to herceptin. But there are numerous 
breast cancer cases, where tamoxifen is ineffective even after estrogen receptor positivity. This lead to search of new prognostic and 
predictive markers and the number of potential markers is constantly increasing due to proteomics and genomics studies. However, most 
biomarkers individually have poor sensitivity or specificity, or other clinical value. It can be resolved by studying various biomarkers 
simultaneously, which will help in better prognosis and increasing sensitivity for chemotherapeutic agents. This review is focusing on 
growth factor receptors, apoptosis markers, signaling cascades, and their correlation with other associated biomarkers in breast cancers. 
As our knowledge regarding molecular biomarkers for breast cancer increases, prognostic indices will be developed that combine 
the predictive power of individual molecular biomarkers with specific clinical and pathologic factors. Rigorous comparison of these 
existing as well as emerging markers with current treatment selection is likely to see an escalation in an era of personalized medicines 
to ensure the breast cancer patients receive optimal treatment. This will also solve the treatment modalities and complications related 
to chemotherapeutic regimens.
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Introduction
Breast cancer is one of the most frequently diagnosed 
cancers  affecting  females.  It  is  estimated  that  this 
disease will afflict one in eight females in America 
during their lifetime. It is estimated that occurrence 
of  breast  cancer  is  26%  of  cancers  from  all  sites. 
An estimated 40,910 (40,460 women, 450 men) breast 
cancer death rate are expected by 2007, accounting 
15% death with respect to other sites.1 Breast cancer 
is characterized by higher expression of epidermal 
growth  factor  receptor  (EGFR)  and  estrogen/
progesterone receptor (ER/PR). It is also found that 
higher  expression  of  vascular  endothelial  growth 
factor (VEGFR-2) is associated with metastasis and 
poor survival outcomes in breast cancer patients. The 
overexpression of either growth factors or its receptors 
leads to abnormal signaling pathways that contributes 
to the progression, invasion, and malignant phenotype. 
Patients suffering from breast carcinoma have a poor 
prognosis because of the lack of effective treatment 
strategies. Detection and identification of prognostic 
markers for predicting therapeutic response is very 
essential for breast cancer treatment. The knowledge 
of  individual  prognostic  marker  remains  poorly 
understood  at  molecular  level  in  breast  cancer 
prognosis  and  prediction  of  particular  treatment 
regimens  and  its  overall  survival.  Most  recently 
gene profiling helps in clustering and segregating the 
genes on the basis of prognosis of disease outcome 
and  the  correlation  of  various  prognostic  factors 
with  metastasis,  ER,  HER-2  status.2,3  In  a  study 
of 295 patients diagnosed with stage I or II breast 
cancer, those classified as having a good prognosis 
profile had a 94.5 ± 2.6 overall 10-year survival rate 
compared  to  54.6% ± 4.4%  for  those  with  a  poor 
profile and the probability of remaining free of distant 
metastases was 50.6% ± 4.5% and 85.2% ± 4.3% in 
the group with poor and a good-prognosis signature4 
and thus the gene profiling can be a more valuable 
prognostic factor in predicting the disease outcome 
than the standard clinical and histogical system of 
classifications based on axillary lymph node status, 
tumor size and tumor grade.5,6 Prognostic and currently 
the predictive markers respond to endocrine therapy 
(tamoxifen  and  raloxifene)  are  ER/PR  and  HER-2 
for identifying breast cancer metastasis responding 
to herceptin.7 Unfortunately, a substantial number of 
tumors are intrinsically tamoxifen-resistant, despite 
estrogen-receptor  positivity,  and  eventually  almost 
all  breast  carcinomas  acquire  resistance  towards 
tamoxifen. This may be due to activation or cross 
talk signaling of other growth factor/cell signaling 
pathways  compensating  the  inhibition  of  upstream 
regulators of particular pathways. It can be overcome 
by  designing  drugs  inhibiting  two  pathways  or 
bidirectional  pathways.  Tumor  resistance  is  also 
acquired due to the overexpression of ATP-binding 
cassette (ABC) transporters.8 This can be overcome 
by designing chemotherapeutic drugs inhibiting ABC 
transporters, and thus overcoming multidrug resistance 
(MDR) and  sensitizing  the  tumors  for  chemotherapeutic 
drugs. Thus, the detailed understanding of cross talk 
signaling  pathways  between  growth  factor,  steroid 
receptors and apoptosis regulators as well as MDR 
properties will lead to the development of new drugs 
that are sensitive and having fewer side effects.
Receptors of breast cancer
Beast cancer patients with the same diagnostic and 
clinical prognostic profile can have markedly different 
clinical  and  survival  out-comes. This  difference  is 
possibly caused by the limitation of our classification 
on  the  basis  of  morphology  without  molecular 
classification.  The  differential  gene  expression 
patterns generated by microarray technology broadly 
classified breast cancer into two sub types ER positive 
(ER+/ErbB-2-)  and  ER  negative  (ER-/ErbB-2+). 
ER- tumors are further grouped into basal-like and 
ErbB-2 subtypes, both with poor prognosis. In contrast, 
ER+ breast cancers could be classified into luminal 
A and luminal B subtypes with significantly distinct 
prognosis,  luminal  A  tumors  displayed  favorable 
outcome, whereas survival of patients with luminal B 
tumors was poor and comparable to those of the ER 
negative ErbB-2 and basal subtypes.2 The molecular 
classifications are found to be strongly associated with 
ER status and moderately associated with grade, but 
not associated with menopausal status, nodal status, 
or tumor size.3
estrogen receptor
ER can be classified into two forms ERα and ERβ, and 
mainly ERα are over-expressed around 70% breast 
cancer cases.9,10 It was found that there is alter or 
increase in expression of α and β forms of ER in tumor 
as compared to normal tissues11 and may contribute to Growth factor receptors and apoptosis regulators
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amplified estrogen response. Both α and β forms are 
homologous especially in DNA binding domain (96%) 
and hormone dependent activation function domain 
(AF-2) (56%). They have the least homology (16%) 
in hormone independent activation function domain 
(AF-1) (Fig. 1a), and probably the signaling cascade 
regulated by AF-1 may be responsible for endocrine 
irresponsive  behavior  of  breast  cancers  expressing 
ERβ. Both ERα and ERβ activated estrogen response 
element  (ERE)  in  response  to  estrogen  and  are 
inhibited with anti-estrogen.12 Estrogen binds to ER 
that  lead  to  series  of  sequential  events  (Fig.  1b), 
finally binding to ERE present in the promoters of 
various target genes13 resulting in cell proliferation. 
ER  complex  can  also  bind  to  transciption  factors, 
such as activator protein (AP-1) or Sp-1 that leads 
to chromatin modification by histone unwinding and 
helping in transcription of genes through alternative 
pathway.  Estrogen  regulated  transcription  at  AP-1 
site acts in two different directions in case of α and β 
forms of ER. Estrogen upregulates genes regulated by 
Ap-1 mediated transcription, whereas anti-estrogen 
downregulates it and reverse is observed in case of 
β  form.  Subsequently,  two  ERs  signal  in  different 
ways depending upon ligands and response elements. 
The different function of selective estrogen receptor 
modulators (SERMs) in breast and uterine tissues may 
also be partially contributed by hormone independent 
AF-1 and hormone dependent AF-2. There are certain 
promoters that require both AF-1 and AF-2 activity, 
whereas  in  other  promoters  both  AF-1  and  AF-2 
function  independently.  Promoters  requiring  AF-2 
or both AF-1 and AF-2 upregulate genes in response 
to estrogen, whereas promoters requiring only AF-1 
activity upregulate genes in response to anti-estrogen. 
It was observed by Tzukerman et al14 that tamoxifen 
(SERMs) does not activate AF-2, therefore, in tissues 
which require only AF-1 activation, tamoxifen is an 
agonist, whereas in tissues which require AF-2, or both 
AF-1 and AF-2, tamoxifen is an antagonist. Moreover, 
AF-1  region  is  involved  in  the  interactions  of  ER 
with coactivators and repressors, further regulating 
the transcribed genes depending on the net ratio of 
coactivators  and  corepressors  in  particular  tissue 
type.15,16 In addition a part of membrane ER (mER) 
is found associated with cell surface via caveolins.17 
Although  classical  concepts  had  assigned  priority 
to  the  nuclear  actions  of  estrogen  receptor,  recent 
studies document the additional importance of mER 
in mediating the rapid effects of 17-β-estradiol (E2). 
It has no transmembrane and kinase domains and is 
known to initiate E2 rapid signals by forming a protein 
complex with many signaling molecules. It mediates 
its  action  via  G-proteins,  growth  factor  receptor-
bound protein-2 (Grb2) and Grb2-associated binder 2 
(Gab-2), receptor tyrosine kinase (RTK) like EGFR, 
insulin like growth factor (IGF) receptor (IGFR) and 
non receptor tyrosine kinase Src.16,18 Phosphorylation 
of Ser118 at nuclear ER by mitogen-activated protein 
kinase  (MAPK1/3)/extracellular  signal-regulated 
kinase  (ERK)17,19  or  phosphatidylinositol  3-kinase 
(PI3-K)/Akt pathways lead to upregulation of estrogen 
regulated genes, whereas glycogen synthase kinase 
3  (GSK-3)  inhibits  the  Ser118  phosphorylation  of 
ER. The signaling and cross talk pathways between 
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Figure 1. Homology of eRα and eRβ. a) estrogen receptor and cross-talk 
signaling with RTK in breast cancer. b) estrogen leads to transcription 
of cell proliferation gene via classical pathway (black arrow). Cross talk 
and bidirectional (gray arrows) signaling between meR, RTK, meR and 
downstream  phosphorylation  of  Ser118  and  167  by  MAPK/eRK  and 
Pi3-K/Akt pathway respectively leads to activation of estrogen regulated 
genes. GSK-3β inhibits (blocking red arrows) phosphorylation of Ser118 
which is further inactivated by Pi3-K/AKT.
Abbreviations: DBD, DNA binding domain; NLS, Nuclear localization 
sequence.Sarkar and Mandal
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growth factors and estrogen signaling is bidirectional. 
It is observed that prolong exposure of anti-estrogen 
irreversibly  causes  cells  to  overexpress  EGFR 
mainly HER-2, and also increased binding of EGFR 
with  mER. This  might  lead  to  increased  signaling 
pathway  of  particular  growth  factor,  decreasing 
estrogen  response  and  hence  development  of  anti-
estrogen  resistance.20  A  full  understanding  of  the 
mechanisms underlying these relationships, with the 
ultimate aim of abrogating specific steps, should lead 
to more-targeted strategies for treatment of hormone 
dependent-breast cancer.
epidermal growth factor receptor
Epidermal growth factor receptors (EGFRs) especially 
EGFR-1 and EGFR-2 (HER-2) play role in breast 
cancer progression. EGFR family of receptors includes 
four closely related receptor tyrosine kinases (RTKs): 
EGFR/HER-1 (ErbB-1), HER-2/neu (ErbB-2), HER-3 
(ErbB-3) and HER-4 (ErbB-4). The highest degree 
of  sequence  homology  (approximately  80%  amino 
acid identity) between HER-2, EGFR and HER-4 lies 
in the tyrosine kinase domain, suggesting that this 
region is essential for the signaling function of these 
molecules. HER-3, by contrast, has four amino acids 
substitutions in its tyrosine kinase domain, leading to 
the suggestion that this receptor may have reduced or 
absent enzymatic activity and its activity is regained 
only after dimerization with other EGFRs.21 The crystal 
structure of HER receptors (HER-1, 3 and 4) are quite 
similar, having domain II-IV contacts. This prevents 
the  intermolecular  dimerization  domain  II  from 
participating in homo- and heterodimerization. Ligand 
binding induces change in structural conformation; 
freeing domain II projection for receptor dimerization, 
that inturn activates RTK activity. There is no such 
contact between domain II-IV, making HER-2 always 
in active state and the preferred partners for other 
HER receptors.22–24 HER-2 overexpression has been 
reported  to  amplify  EGFR  signaling.  HER-2/neu 
gene  amplification  is  most  common  representing 
25%–30%25 of breast cancer of ER- type and herceptin 
shows a promising clinical result with HER-2 positive 
breast cancers. Increase in HER-2 correlates with poor 
prognosis  and  increased  propensity  for  metastasis. 
HER-2  amplification  results  in  a  50  to  100-fold 
increase in the number of surface receptors on cancer 
cells compared to the normal mammary epithelium. 
HER-2 gene amplification and oncogenic mutations 
constitutively  activate  the  HER-2  homodimeric 
tyrosine kinase.26 Elevated HER-2 activity can reduce 
the  general  growth  factor  dependence  of  HER-2 
amplified cells though prolonged stimulation of the 
Ras/Raf/Mitogen-activated  protein  kinase  (MAPK) 
pathway, and confers resistance to hormonal therapy.27 
Upon dimerization of EGFRs by EGF and Hergulin 
(HRG) and receptor phosphorylation, Shc binds the 
receptor which further transmits the signal to GRB2, 
SOS and Ras which inturn leads to an increase in Raf 
kinase activity. Once activated, Raf phosphorylates 
and activates its major substrates mitogen activated 
extracellular  signal  regulated  kinase  activating 
kinases  (MEK)  family  which  includes  MEK1  and 
MEK2, which in turn phosphorylate and activate the 
MAPKs (ERK1 and ERK2). MAPK family of kinases 
also  includes  p38MAPK  and  c-Jun-N-terminal  kinase 
(JNK).  Inaddition  to  activation  of  Raf/MEK/ERK 
pathways,  Ras  and  phosphorylated  EGFR  family 
members  stimulates  PI3-K  activity  by  binding  to 
p110 subunit and p85 subunit of PI3-K respectively 
(Fig.  2). Activated  PI3-K  phosphorylate  substrates 
like  phosphatidylinositol-4  phosphate  and 
phosphatidylinosital  4,  5-bisphosphate  to  yield  3, 
4-bisphosphate [PI(3,4)P2] and phosphatidylinositol 
3,4,5-trisphosphate [PI(3,4,5)P3]. This in-turn recruits 
phosphoinositide  dependent  kinase-1  (PDK-1)  and 
Akt  family  kinases  to  the  plasma  membrane  and 
activate  them.  This  signal  transduction  cascade 
initiated by PI3-K is referred to as the PI3-K/PDK1/
Akt pathway. This cascade can prevent apoptosis.28,29 
Although  HER-2  gene  amplification  and  protein 
overexpression have been extensively studied in breast 
cancer, data on EGFR overexpression in breast cancer 
are limited. EGFR overexpression and its activating-
mutations at exons 18–21 in lung cancers have been 
extensively studied. It has been found that there is 
a strong response of tyrosine kinase inhibitors (e.g. 
erlotinib and gefitinib) to lung cancers exhibiting EGFR 
activating-mutations.  These  mutations  selectively 
activate AKT and signal transduction and activator 
of  transcription  (STAT)  signaling  pathways,  which 
promote cell survival. Gefitinib was found to bind the 
ATP pocket of catalytic domain of EGFR kinase, and 
thus inhibiting the anti-apoptotic signals transduced 
by mutant EGFR.30 Though there is lack of data of 
EGFR  activating  mutations  associated  with  breast Growth factor receptors and apoptosis regulators
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cancer, but EGFR overexpression has been reported 
to occur around 20%–36% breast cancer cases. These 
may be candidates for anti-EGFR therapies. Besides, 
there  is  strong  synergy  of  EGFR  with  HER-2,  so 
blocking both receptors may be critical. Interestingly, 
EGFR and HER-2 coexpression in breast cancer was 
recently  associated  with  reduced  overall  survival 
(OS)  and  disease-free  survival  (DFS).31  It  is  also 
increasingly clear that the high cell-surface HER-2 
density  that  accompanies  gene  amplification  alters 
the normal equilibrium of EGFR dimers in favor of 
HER-2 containing heterodimers, thus altering ligand 
dependant  signaling  mechanisms.  The  oncogenic 
potency of heterodimers, EGFR/HER-2 for example, 
is  significantly  enhanced  compared  to  EGFR 
homodimers by several processes that prolong receptor 
signaling activity. HER-2/neu + breast cancer is also 
characterized by higher expression of MDR1, S100 
calcium-binding protein P, fatty acid synthase, Ras 
related GTPases, RAL-B, RAB6A, fibronectin 1, and 
syndecan1 and lower expression of c-kit and c-myc.32 
Moreover it is found that s-HER-2 elevation in early 
breast cancer correlates with the principal criteria of 
tumor aggressiveness and vascular invasion.33 It can 
act  as  independent  prognostic  factor  enabling  to 
identify patients likely to benefit from more aggressive 
treatments at the early stages of tumor metastasis.
vascular endothelial growth 
factor receptor
Breast cancer particularly metastatic breast cancer 
and  angiogenesis  is  characterized  by  upregulation 
of  VEGFR.  It  is  a  member  of  receptor  tyrosine 
kinase family. VEGFR family of receptors consists 
of  VEGFR-1  (flt-1),  VEGFR-2  (KDR/flk-1)  and 
VEGFR-3  (flt-4)  and  soluble  form  of  VEGFR-1 
(sVEGFR-1),  an  intensive  negative  counterpart  of 
VEGF.34  VEGFR-1  and  VEGFR-2  is  mainly  responsible 
for angiogenesis whereas VEGFR-3 is responsible 
for  lymphogenesis. There  are  common  as  well  as 
unique  ligands  for  VEGFRs.  VEGF-A,  VEGF-B 
binds to VEGFR-1. VEGF-A, VEGF-C and VEGF-
D binds to VEGFR-2. VEGF-C, VEGF-D binds to 
VEGFR-3. VEGFR-1 and VEGFR-2 are structurally 
similar,  consisting  of  an  extracellular  ligand 
binding  domain  with  seven  immunoglobulin  (Ig)-
like motifs, a single transmembrane domain and a 
juxtamembrane  domain,  a  kinase  domain  split  by 
a  kinase  insert,  and  a  carboxyl  terminus.  Overall, 
there  is  43.2%  sequence  homology  between 
VEGFR-1 and VEGFR-2. The extracellular domain 
of  VEGFR-1  and  VEGFR-2  displays  33.3% 
homology and the cytoplasmic region displays 54.6% 
homology.  The  kinase  domain  of  VEGFR-1  and 
VEGFR-2 represent the most conserved region with 
70.1% homology. In contrast, the carboxyl terminus 
represents the most divergent region with only 28.1% 
sequence  homology.  This  carboxyl  terminus  is 
responsible for cell signaling for angiogenesis. The 
difference in sequence of carboxyl terminus between 
VEGFR-1  from  that  of  VEGFR-2  is  responsible 
for  the  former  kinase-impaired  activity.  Although 
ligands have strong affinity towards VEGFR-1 than 
VEGFR-2, but it is VEGFR-2 that responds to almost 
all of the cellular responses to VEGF. Upon VEGF 
binding,  receptor  dimerization  takes  place  leading 
to transphosphorylation, an increase in the intrinsic 
catalytic  activity  and  creation  of  binding  sites  on 
the RTKs to recruit cytoplasmic signaling proteins 
that activates ERK1/2 pathway and also PI3-K/Akt 
(Fig.  2)  pathways.  In  the  unstimulated  form,  the 
activation loop orients tyrosine residues toward the 
activation sites of the enzyme and thereby sterically 
prevents  binding  to  ATP-Mg2+.  After  binding  of 
ligand and dimerization of receptors, phosphorylation 
of tyrosine residues in the catalytic loop takes place 
that orients the inhibitory loop away from the active 
site enabling the RTK to bind ATP-Mg2+. It finally 
acts as the binding sites and phosphorylates SH2- 
and  PTB-  containing  molecules.  It  is  found  that 
solid  tumors  are  characterized  by  the  presence  of 
hypoxic  pockets,  and  VEGFs/VEGFRs  signaling 
are  responsible  for  survival  and  aggressive  nature 
of  tumor  cells.  Hypoxia  induced  VEGF  signaling 
and  constitutively  activates  PI3-K,  stimulates Akt 
activity  and  hence  inhibits  apoptosis  and  favors 
cell  survival.  There  are  also  reports  that  VEGF 
signaling can induce the expression of anti-apoptotic 
Bcl-2,  Bcl-xL  and  promotes  cell  survival.35,36  In 
addition,  VEGFs/VEGFRs  signaling  promote  cell 
adhesion  and  migration  through  activated  αvβ3 
integrin in breast cancer. Breast cancer cells mainly 
express  VEGF-A,  VEGF-B,  VEGF-C  and  their 
receptors  VEGFR-1,  VEGFR-2  and  neuropilin 
(NP-1/NP-2).37  VEGFR-1  is  associated  with  poor 
prognosis,  particularly  those  with  node  negative Sarkar and Mandal
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tumors, with high risk of metastasis and relapse.38,39 
VEGFR-1  immunodetection  may  further  be 
considered as a potential tool for evaluating tumor 
aggressiveness and therapeutic strategies in breast 
cancer  whereas  VEGFR-2  positive  tumor  surface 
was not correlated with survival or with metastasis 
risk and relapse.VEGFR-2 mainly functions in VEGF 
signaling whereas VEGFR-1 functions as a decoy 
receptor  in  VEGF  signal  regulation.  VEGFR-3  is 
predominantly expressed in endothelium of lymphatic 
vessels.  It  promotes  tumor  lymphogenesis  and 
lymphatic  metastasis.  VEGF-C/VEGFR-3  is  also 
found in tumor tissues of breast cancer, and played 
a role in upregulating neural cell adhesion moleculer 
CNTN-1  through  Src/p38  MAPK  pathway.40 
It promotes cell invasion via rearrangement of actin 
cytoskeleton. Neuropilins, which are receptors for the 
collapsin/semaphorin family responsible for neural 
cell guidance, binds to VEGF (VEGF165, but not 
to VEGF121). VEGF-A secretion by breast cancer 
cell lines MDA-MB-468, T-47D, MCF-7, HBL-100, 
and MW1 were about 2.3 to 37.3 ng/ml for 106 cells 
for 48 hours, which was higher above the biological 
activity  of  VEGF-A  (1–50 pg/ml),37  indicating 
the  role  of  VEGF  in  breast  cancer  progression. 
VEGFR-2 phosphorylation was detected above the 
baseline in case of epithelial breast cancer cells than 
in endothelial breast cancer cell line, PAEC/KDR, 
without external VEGF stimulation. But there was 
a  marked  increase  in  VEGFR-2  phosphorylation 
following  stimulation  with  VEGF.  Weigand  et al 
observed  that  VEGF-A-induced  increase  in  Akt 
phosphorylation  in  T47D  cells,  while  stimulation 
of  MDA-MB-468,  HBL-100,  MCF-7  and  MW1 
with  VEGF-A  resulted  in  an  increase  in  ERK1/2 
phosphorylation.  Therefore  VEGF  stimulation 
leads to phosphorylation of VEGFR-2 which in turn 
activates either ERK1/2 or PI3-K/Akt pathways.
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Figure 2. epidermal growth factor receptor and vascular endothelial growth factor receptor signaling in breast cancer.Growth factor receptors and apoptosis regulators
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Apoptosis
Normal  breast  development  is  controlled  by  a 
balance  between  cell  proliferation  and  apoptosis, 
and there is strong evidence that tumor growth is not 
just a result of uncontrolled proliferation but also of 
reduced apoptosis. The balance between proliferation 
and apoptosis is crucial in determining the overall 
growth  or  regression  of  the  tumor  in  response  to 
chemotherapy,  radiotherapy  and,  more  recently, 
hormonal  treatments.  All  of  these  act  in  part  by 
inducing apoptosis41–43 and inhibiting cell proliferation. 
The molecular understanding of cell proliferation and 
apoptosis signaling (Fig. 3) could allow individually 
tailored  treatments  to  maximize  tumor  regression 
and  its  efficacy.  Cancer  cells  overcome  cell  death 
or  apoptosis  due  to  mutation  of  tumor  suppressor 
genes and impaired apoptotic machinery executing 
cell  death.  The  apoptotic  pathway  is  controlled 
by  a  diverse  range  of  cell  signals  which  may 
originate  either  extracellularly  (extrinsic  inducers) 
or intracellularly (intrinsic inducers). These signals 
may positively or negatively induce apoptosis. The 
extrinsic pathway is activated by binding of ligands 
such as FasL and TNF to FAS and TNFR, inducing 
the  formation  of  death  induced  signaling  complex 
(DISC).  DISC  in  turn  recruits  caspase-8  through 
FADD (Fas-Associated Death Domain) and promotes 
the  cascade  of  procaspase  activation  and  finally 
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Figure 3. Apoptosis and croos-talk signaling with RTK in breast cancer.Sarkar and Mandal
54  Breast Cancer: Basic and Clinical Research 2009:3
caspase-7 leading to apoptosis. The intrinsic pathway 
is triggered by various extracellular and intracellular 
stresses, such as growth-factor withdrawal, hypoxia, 
DNA damage and oncogene induction. Signals that 
are transduced in response to these stresses converge 
mainly on the mitochondria. A series of biochemical 
events is induced that results in the permeabilization 
of  the  outer  mitochondrial  membrane,  the  release 
of cytochrome-c and other proapoptotic molecules, 
the  formation  of  the  apoptosome,  a  large  protein 
complex  that  contains  cytochrome-c,  apoptotic 
protease activating factor 1 (APAF1) and caspase-9 
and  finally  caspase-3/7  activation  and  cell  death.44 
There is a cross talk between extrinsic and intrinsic 
pathway. Activated caspase-8 cleaves Bid, and the 
COOH-terminal  part  translocates  to  mitochondria 
where it triggers cytochrome-c release.45,46 Apoptosis 
is mainly governed by the net ratio of pro-apoptotic 
and anti-apoptotic Bcl-2 family members (Table 1). 
Higher Bax/Bcl-2 ratio predicts good response for 
chemotherapy in breast cancers, indicating apoptosis. 
There are at least 19 Bcl-2 family members that have 
been  identified  in  mammalian  cells,  with  several 
others found in viruses.47 They possess at least one of 
the four conserved motifs known as Bcl-2 homology 
domains  (BH1  to  BH4).48,49  Most  anti-apoptotic 
members  contain  all  four  of  these  domains.  Some 
pro-apoptotic Bcl-2 family proteins possess only the 
BH3 domain, which is essential for their function,50,51 
indicating  the  role  of  BH3  domain  in  apoptosis. 
These  pro-  and  apoptotic  Bcl-2  family  members 
will be studied in detail to understand and unveil the 
chemoresistance in breast cancers.
Apoptosis regulators
Prognostic markers of breast cancers (Table 2) include 
apoptotic  regulators,  growth  factors,  proteases  and 
topoisomearse.  Apoptotic  regulation  is  controlled 
by  Bcl-2  family  of  proteins.  The  expression  of 
Bcl-2 protein has been shown to suppress apoptosis 
in  response  anticancer  drugs.52,53  Therefore,  Bcl-2 
may mediate chemoresistance in some patients and 
Bcl-2  could  be  a  target  for  the  development  of 
new anticancer therapy. Inhibition of expression of 
Bcl-2 family members by antisense oligonucleotide 
or  dominant  negative  inhibitor  Bcl-xs  has  already 
been  shown  to  promote  apoptosis  and  to  sensitize 
cells  to  chemotherapy-induced apoptosis.54  Despite 
the antiapoptotic and chemoresistant effects favoring 
tumor  survival,  Bcl-2  prolongs  cell  cycle  and 
decreases tumor cell proliferation, and these functions 
may account for the association of Bcl-2 in favorable 
breast cancer outcomes. In humans Bcl2 is expressed 
in about 80% of breast cancers55,56 in women with 
primary  tumors,  having  either  node  positivity  or 
negativity and is correlated with the expression of ER 
and PR. Zhang et al57 observed that Bcl-2 gradually 
decreases during the development of breast cancer, 
i.e. from a normal epithelium (96%) to intraductal 
carcinoma (79%), and from intraductal to invasive 
carcinoma  (45%),  and  reverse  is  observed  in  case 
of  p53  expression.  Consistent  with  these  findings, 
Haldar  et al58  reported  that  transfection  of  mutant 
p53  into  a  p53-wild-type  breast  cancer  cell  line 
suppressed expression of Bcl-2. Major correlations 
between  Bax  protein  and  outcome  have  not  been 
observed,  although  in  patients  with  breast  cancer, 
a reduced expression of Bax was correlated with a 
poor response to chemotherapy and metastatic breast 
cancer.59,60 Restoration of Bax expression in breast 
cancer  cell  lines  increased  sensitivity  to  cytotoxic 
drug therapy and also suppressed tumorigenesis.61,62 
However, in breast cancers, no correlation between 
the  percentages  of  Bax  and  p53-immunopositive 
tumor cells was observed when examined as either 
dichotomous  or  continuous  variables,  although 
p53  binds  with  Bax  gene  promoter  and  hence 
Table 1. Bcl-2 family members.
Anti-apoptotic pro-apoptotic
BCL-2 BAX
BCL-XL BAK
MCL-1 BOK
A-1/BFL-1 BAD
BCL-w BiD
BOO/DivA BiK
NR-13 BLK
HRK
BiM
BNiP3
NiX
NOXA
esteva and Hortobagyi.47Growth factor receptors and apoptosis regulators
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acts  as  transcriptional  activator.63  Moreover  Bax 
immunostaining  was  not  significantly  correlated 
with HER-2, cathepsin D or S phase fraction, but 
was  positively  associated  with  Bcl-2.  The  other 
antiapoptotic  proteins  related  to  Bcl-2  are  Bcl-xL 
and  Mcl-1.  The  remarkable  structural  similarity 
between the Bcl-2 and Bcl-x genes suggests that they 
have evolved from a common ancestral gene by way 
of  gene  duplication.64  Through  alternate  splicing, 
Bcl-x  can  encode  several  proteins,  including  the 
Bcl-xL (long) protein which inhibits apoptosis and 
a shorter isoform Bcl-xS which promotes apoptosis 
by acting as a trans-dominant inhibitor of Bcl-2 and 
Bcl-xL. Bcl-xL inhibits cytochrome-c redistribution 
from inter membrane space of mitochondria to cytosol 
by blocking both membrane hyperpolarization and 
mitochondrial swelling in response to several sets of 
apoptotic stimuli.65 Moreover, recent studies report 
that Bcl-xL protein interacts with Apaf-1 to inhibit the 
caspase activation involved in apoptosis,66 increases 
metastatic potential of breast cancer. Increased levels 
of Bcl-xL expression were found in a subset of primary 
human breast carcinomas, mainly in undifferentiated 
histological grade (HG) III tumors.67,68 In the breast, 
their overexpression could protect breast cancer cells 
from p53-mediated apoptosis.69 More recently BAG-1, 
a multi functional protein that blocks apoptosis, has 
been correlated with improved survival in early stage 
breast  cancer.  Again,  this  seemingly  contradictory 
finding in an inhibitor protein reflects the complex 
mechanisms in which these proteins work; BAG-1 is 
known to interact with other members of the Bcl-2 
family as well as heat shock proteins and estrogen 
receptors. Another  member  of  pro-apoptotic  Bcl-2 
family consists of Bad that bind to anti-apoptotic Bcl-2 
and Bcl-xL, thus induce apoptosis. In fact, in normal 
human breast cells, Bad levels are relatively high in 
comparison with those in other organs,70 suggesting 
that Bad might have a special role in the breast. Bad is 
regulated by growth factors and cytokines, stimulating 
Bad  phosphorylation  on  specific  serine  residues: 
S112,  S136,  S155  and  S170.  Phosphorylation  of 
Bad  on  these  residues  promotes  its  binding  to, 
and  subsequent  cytosolic  sequestration  by,  14-3-3 
proteins.  Thus  phosphorylation  at  serine  residues 
prevents Bad from associating with Bcl-2 or Bcl-xL 
on the mitochondrial outer membrane, leaving these 
proteins free to exert their anti-apoptotic function.71 
Indeed,  Gilmore  et al72  showed  that  transient  Bad 
overexpression enhances the sensitivity of mammary 
Table 2. Bio-molecular markers of breast cancers.
Markers Occurrence (%) Treatment References
eGFR 17% Chemotherapy 97
HeR-2 25% Monoclonal Humanized antibody 25,76
veGFR 64% (invasive  
breast cancer)
Chemotherapy 34,98
eR and PR 70%–80% endocrine therapy 99,10
BRCA1 and BRCA2 2%–4% Chemotherapy and Radiotherapy 100
P53 25%–30% Chemotherapy 101–103
P21 (10% of cells positive) 65% Chemotherapy 104
Bcl-2 80% Chemotherapy, antisense RNA 55,56
Topoisomerase ii α 50.2% Chemotherapy: Anthracycline 105
uPA and PAi-1 46% Adjuvant chemo or endocrine therapy 106,107
Caspase-3 75.2% Chemotherapy 108
*TiP30/CC3 83.3% Genetherapy 109,110
**Ki-67 56% Chemotherapy and endocrine therapy 111,112
*TiP30/CC3 is metastatic tumor suppressor gene. Decrease in expression of TiP30 is observed in 48% of breast cancer cases and 83.3% of TiP30 
negativity tumors had lymph node metastasis and vascular invasion. **Ki-67 cut off value for primary (P) tumors is 10% and 15% for metastatic (M) tumors. 
P-/M- = 44%, P+/M+ = 27.3%, 14%, P-/M+ = 21.1%, P+/M- = 7.2%.
Abbreviations: uPA, urokinase plasminogen activator; PAi-1, plasminogen activator inhibitor-1.Sarkar and Mandal
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cells to apoptosis, perhaps because the S112 and S136 
kinases become limiting. On the other hand, primary 
cultures  of  Bad-/-  mammary  cells  are  no  longer 
sensitive  to  ZD1839-induced  apoptosis,  suggesting 
that Bad might be the important pro-apoptotic effector 
downstream of the EGFR. Survivin, a member of the 
inhibitor of apoptosis (IAP) gene family, containing 
only a single baculoviral IAP repeat (BIR) domain. 
Survivin  is  overexpressed  in  most  human  cancers, 
including  breast,  but  is  not  expressed  in  normal 
tissue.  84%  of  breast  carcinoma  showed  nuclear 
survivin  expression.73  Survivin  is  associated  with 
more aggressive behavior and decreased survival in 
a variety of tumor types. It regulates the G2/M phase 
of the cell cycle by associating with mitotic spindle 
microtubules, and it directly inhibits caspase-3 and 
caspase-7  activity.  There  is  a  gradual  rise  in  the 
expression of caspases 3, 6 and 8 and the expression 
of these caspases are strongly associated with increase 
in apoptosis, with a direct relationship between the 
apoptotic index and the histological aggressiveness of 
a breast lesion.74 Expression of genes such as p53 and 
c-erb-B2 are also increased in higher grade tumors. 
It  is  possible  that  such  genes  may  be  responsible 
for  the  increased  apoptotic  rate  observed  in  these 
tumors.
Molecular targets and chemotherapeutic 
drugs
Breast cancer is characterized by overexpression of 
ER/PR,  EGFR,  HER-2  and VEGFR-2,  along  with 
Bcl-2  and  downreguation  of  p53.  At  present,  the 
circle of agents with an established chemopreventive 
effect  is  restricted  to  tamoxifen  and  raloxifene 
in  breast  cancer.  However,  in  recent  years,  there 
has  been  an  exponential  increase  in  the  study  of 
agents  (Table  3)  that  have  a  chemopreventive 
potential against molecular targets of breast cancer. 
The treatment for cancer cells that may have spread 
beyond the breast, lymph nodes and nearby tissues 
is  a  combination  of  either  hormone  therapy  (anti-
estrogen)  and/or  chemotherapy.  Metastatic  breast 
cancer (MBC) develops in 30%–40% of patients with 
breast carcinoma and patients with MBC have a median 
survival of about 2 years and, therefore, new anticancer 
agents  are  urgently  required.75  Chemotherapeutic 
drugs are applied to patients depending upon size, 
lymph  node  status,  ER  and  PR,  and  HER-2/neu 
over-expression. Herceptin is a monoclonal antibody 
targeting HER-2 overexpression breast cancer cells. 
It  induces  HER-2  receptor  downmodulation  and, 
as a result, inhibits Ras/Raf/MAPK and PI3-K/Akt 
pathways leading to inhibition of cell proliferation and 
apoptosis and also blocking cell cycle progression by 
inducing the formation of p27/Cdk2 complexes.25,76,77 
It  is  found  that  addition  of  herceptin  along  with 
other chemotherapeutic drugs for early stage HER-2 
positive breast cancers reduced the risk of recurrence 
and death by 52% and 33% respectively, compared to 
chemotherapy alone.78,79 There is another humanized 
monoclonal antibody, pertuzumab (2C4) that binds 
to different epitope than that of herceptin. It mainly 
inhibits  HER-2  heterodimerization  with  HER-1, 
HER-3 and HER-4 and thus inhibits downstream cell 
proliferation pathways of HER-2 based heterodimers 
in  cells  with  low  or  high  expression  of  HER-2 
receptors.25 Bevacizumab (Avastin) is a monoclonal 
antibody  against  VEGF,  thus  help  in  inhibiting  in 
angiogenesis.  It  is  approved  by  FDA  in  2008  and 
used in metastatic breast cancer as adjuvant therapy 
along  with  5-  florouracil  (5-FU),  oxaliplatin.  The 
most common chemotherapeutic drugs recommended 
to  be  used  in  combination  in  early  breast  cancer 
are  cyclophosphamide,  methotrexate,  fluorouracil, 
Table 3. Drugs used for breast cancer treatment.
Drugs Molecular targets
Tamoxifen eR
Raloxifene eR
Steroidal Ai: exemstane Aromatase/estrogen
Non-steroidal Ai: 
Anastrozole and 
Letrozole
Aromatase/estrogen
Herceptin HeR-2
Pertuzumab HeR-2
Bevacizumab veGF/veGFR
Gefitinib eGFR
Zactima veGFR/eGFR
Doxorubicin DNA, Topoisomerase ii 
complex
Taxane  
(Paclitaxel, docetaxel)
β subunit of tubulin, Bcl-2
5-Fluorouracil, 
capecitabine (prodrug)
Thymidylate synthaseGrowth factor receptors and apoptosis regulators
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doxorubicin  (adriamycin),  epirubicin,  paclitaxel 
(Taxol), and docetaxel (Taxotere). Paclitaxel (PAC) 
and  docetaxel  (DOC)  are  clinically  effective  anti 
neoplastic  agents  and  excellent  choices  for  the 
first-  and  second-line  treatment  of  patients  with 
MBC.80,81 Taxanes bind to β-subunit of tubulin, retard 
microtubule  depolymerization,  impair  mitosis,  and 
block progression through the cell cycle. In addition, 
the taxanes inactivate the Bcl-2 protein and induce 
apoptosis in breast cancer cells in vitro.82,83
Better  understandings  of  breast  cancer  at 
molecular  level  helps  in  designing  new  potential 
anticancer  drugs  that  target  specific  receptors  and 
tumors,  thus  increasing  the  efficiency  and  having 
lesser side effects than conventional chemotherapy. 
Such targeted therapies as adjuvant therapy benefits 
the  patients  in  advanced  diseases,  delay  the  time 
of  cancer  reoccurrence  as  well  as  reverses  the 
hormone-  and  chemo-resistance.  Lapatinib,  a  dual 
tyrosine kinase inhibitor of EGFR and HER-2, inhibits 
autophosphorylation of tyrosine kinase residue and 
exerts greater biologic effects in inhibiting signaling 
pathways of cell proliferation and inducing apoptosis 
than  inhibition  of  either  receptor  alone.84  It  has 
been approved by FDA in 2007 for use in patients 
with advanced metastatic breast cancer along with 
chemotherapeutic  drugs  like  taxanes,  herceptin, 
and capecitabine. It is effective in delaying cancer 
progression in HER-2 positive advanced metastatic 
breast cancer women who have become resistant to 
Herceptin.85 There is another class of drugs that fall 
under hormone therapy. They can be further divided 
into selective estrogen receptor modulators (SERMs) 
and aromatase inhibitors (AIs). Tamoxifen (Nolvadex) 
and raloxifene compete with estrogen in binding ER. 
Upon binding the receptor complex may act as agonist 
by  binding  with  co-activators  and  enhance  the 
estrogenic  signaling  responses  or  antagonist  by 
binding  with  co-repressors  and  thus  inhibiting  the 
estrogenic responses. Moreover the outcome of the 
response is also governed by the type of tissue and 
the RTK by enhancing the estrogenic responses. Thus 
the final outcome is governed by the balance between 
antagonist and agonist effect of SERMs.86 Tamoxifen 
is used in ER+ metastatic breast cancer as adjuvant 
therapy in a pre and post menopausal women. It is 
cytostatic  drug  leads  to  accumulation  at  G0/G1 
phase perhaps by forming the complex p21/CDK2.87 
Tamoxifene  also  leads  to  endometrial  cancer  after 
prolong use, whereas raloxifene doesn’t and it is as 
effective  as  tamoxifene  and  used  in  treating  ER+ 
invasive breast cancer patients with postmenopausal 
osteoporosis.88,89 AIs include anastrozole (Armidex), 
letrozole (Femara) and exemestane (Aromasin). AIs 
block the conversion of androstenedione into estrogen 
and are found to be more effective than tamoxifen in 
treating  post  menopausal  women  with  ER+  breast 
cancers.90–92 Though, lot of cytotoxic drugs is available, 
but still challenges in treatment remains. Many tumor 
cells become resistant to commonly used cytotoxic 
drugs due to the overexpression of ABC transporters. 
Two proteins, P-gp (MDR-1, ABCB1) and MRP-1 
(ABCC1) have been demonstrated to pump a wide 
selection  of  the  most  commonly  used  anti-cancer 
drugs  and  their  overexpression  correlates  broadly 
with  negative  treatment  response  characteristics  in 
many different forms of cancer. It is also found that 
genetic alteration or gene amplification of metastasis 
gene metadherin (MTDH) is associated with more 
than  40%  breast  cancer  cases  with  poor  clinical 
outcomes.93 These findings establish that anticancer 
drugs targeting ABC transporters and MTDH can be 
used in increasing the chemotherapeutic efficacy and 
reducing metastasis risk.
conclusions
The prognosis and over all survival of breast cancer 
has improved over years, with current 10 year relative 
survival  of  about  70%  in  western  population.94,95 
Positive lymph node status, tumor size, PR and ER, 
HER-2  are  the  most  reliable  prognostic  factors  in 
predicting overall as well as disease free survival of 
breast cancer patients.96 The knowledge of individual 
prognostic  marker  remains  poorly  understood  at 
molecular  level  in  breast  cancer  prognosis  and 
prediction  of  particular  treatment  regimens  and  its 
overall survival. Gene profiling, the future diagnostic 
tool, help in clustering and segregation of genes based 
on disease outcome and correlation with established 
biomarkers  ER/PR  and  HER-2.  It  has  the  potential 
to find new biomarkers and solve the molecular basis 
of chemoresistance. It is expected that more patient 
samples and gene profiling datas will help in validation 
of various prognostic factors i.e. EGFR-1, cell cycle 
molecules, apoptosis related proteins, VEGF, sVEGFR, 
matrix  metalloproteinase  (MMP)-2  and  MMP-9, Sarkar and Mandal
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tissue  inhibitors  of  metalloproteinases,  plasminogen 
activators  and  inhibitors,  etc.  that  are  currently  in 
investigation for primary and advanced breast cancer. 
The increasing number of biomarkers associated with 
breast cancers should yield a better test for prognosis 
and  thus  increase  the  screening  sensitivity  between 
healthy and cancer at early stages. Moreover, it’ll also 
help in designing cancer therapies and drugs that are 
tailored to unique characteristics of each individual and 
tumor. Such rational therapies will have less adverse 
effects than conventional therapy and will have better 
outcome in overall and disease free survival.
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